Clinical Trials Logo

Fragile X Syndrome clinical trials

View clinical trials related to Fragile X Syndrome.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04823052 Withdrawn - Fragile X Syndrome Clinical Trials

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

IMPACT-FXS
Start date: May 25, 2022
Phase: Phase 2
Study type: Interventional

This study is to investigate the safety, tolerability and efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in males with Fragile X Syndrome (FXS) with confirmed full FMR1 mutation treated over a 10 week period in an outpatient setting.

NCT ID: NCT04314856 Withdrawn - Clinical trials for Fragile X Syndrome (FXS)

Novel Clinical Target in Fragile X Syndrome

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder (ASD). The investigators wish to examine brain distribution of sigma-1 receptors in young adult males with FXS using 18F-FTC-146 PET. This project will study the distribution of sigma-1 receptors in 15 young (18-30 years) male adults with FXS compared to 5 healthy adult volunteers.